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Abstract
Gestational diabetes mellitus (GDM) is a condition that affects the wellbeing of mother and fetus. 
Women with GDM are at risk of type 2 diabetes mellitus in the future, while fetal exposure to hyper-
glycaemia in-utero may affect their glycometabolic profile later in life. Appropriate screening and 
management of this problem is important in ensuring good pregnancy outcomes. In this review, the 
clinical implications, the various ways to screen and diagnose GDM, and management strategies 
during pregnancy will be discussed. For years, insulin is the mainstay of treatment if medical nutri-
tion therapy fails to maintain adequate glycaemic control, but use of other oral pharmacotherapy 
may gain greater acceptance in the future. Following delivery, ongoing follow-up of these women 
is worthwhile as early intervention through lifestyle or pharmacotherapy may prevent the deve-
lopment of diabetes.
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Introduction
Gestational diabetes mellitus (GDM) is defined as glucose intolerance which is first detected during 
pregnancy [1]. Women with GDM are distinct from women who have pre-existing type 1 or type 2 
diabetes mellitus at the time of pregnancy. The prevalence of GDM worldwide is difficult to determine, 
because the diagnostic criteria adopted by different countries vary greatly, and certain ethnic groups 
have higher risks of developing GDM [2]. In a large study in United Kingdom involving over 11,000 
women, the incidence of gestational diabetes was found to be 0.4% in Caucasians, 1.5% for Africans, 
up to 7.3% in East Asians and 4.4% among women from South Asia [3]. In United States, the estimated 
prevalence was 7%, but this may change following adoption of the new diagnostic criteria for GDM in 
accordance with the International Association of Diabetes and Pregnancy Study Groups (IADPSG) [1]. 
Apart from ethnicity, other risk factors for GDM include older age, obesity, family history of diabetes, 
past history of delivery of macrosomic babies and past history of GDM [4].
In this review, we will discuss the clinical relevance of GDM, the diagnostic criteria and screening stra-
tegies, management principles as well as post-partum care of women with GDM.
Adverse effects of gestational diabetes
Insulin sensitivity and secretion vary during different stages of pregnancy. In first trimester as well as 
early in second trimester, an increase in insulin sensitivity occurs mainly due to the relatively higher 
levels of estrogens. However, in the late second and early third trimesters, the increase release of hor-
mones including human placental lactogen, leptin, prolactin, and cortisol from the placenta are re-
sponsible for the increase in insulin resistance [5]. When the woman’s insulin secretory capacity cannot 
cope with the increase in demand, glucose intolerance develops.
Glucose is transported freely from maternal to fetal circulation, whereas maternal insulin does not 
cross the placental barrier [6]. In 1952, in his PhD thesis, Jorgen Pedersen postulated that maternal 
hyperglycemia, as seen in women with GDM, led to fetal hyperglycemia that, in turn, evoked an exag-
gerated fetal insulin response [7]. Macrosomia is generally defined as birth-weight in excess of 4,000-
4,500 g [6]. Mean blood glucose level (BGL) strongly correlated with neonatal birth-weight in women 
with GDM, and the degree of macrosomia was also found to be associated with fetal plasma insulin 
immune-reactivity and blood pH [8,9]. Fetal pancreatic beta-cell hyperplasia is implicated in the pa-
thogenesis of fetal acidemia and macrosomia [9]. Large fetuses are susceptible to injury such as shoul-
der dystocia and newborn asphyxia during vaginal birth delivery.
It was generally believed that offspring of women with GDM do not have an increased risk of conge-
nital abnormalities, as fetal exposure of hyperglycaemia is more prominent in second and third trime-
ster of pregnancy. However, in a meta-analysis, a higher risk of major congenital malformations was 
observed in infants of women with gestational diabetes with relative risk of 1.16 in cohort studies and 
odds ratio (OR) of 1.4 in case control studies [10]. This may be partly due to the inadvertent inclusion 
of some women with overt hyperglycemia or pre-existing diabetes in the analysis. However, it is also 
possible that in some women with GDM, mild degree of hyperglycaemia during first trimester, which 
is the critical period for organogenesis, is sufficient to result in fetal abnormality. Even though this risk 
in GDM is increased, it is still much lower than that in women with pre-existing diabetes.
A number of studies confirmed that pregnancies complicated by GDM were associated with a higher 
risk of adverse outcomes. The Hyperglycaemia and Adverse Pregnancy Outcome Study (HAPO) is 
the largest study to date involving over 25,000 women at 15 centers from 9 countries that assessed the 
relationship between glycaemia and obstetric outcomes [11]. The main findings of the study were that 
the fasting, 1-hour and 2-hour glucose levels on the 75 gram oral glucose tolerance test (OGTT) all had 
positive correlations with macrosomia and cord C-peptide levels above 90th percentile [11].
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In addition, weaker associations were found between glucose levels and need for Caesarian section as 
well as neonatal hypoglycaemia. These relationships persisted after adjustments of confounders inclu-
ding maternal age, body mass index and other clinical variables, suggesting that influence of maternal 
glycemia on fetal outcomes is a basic biologic phenomenon. Interestingly, the association appeared to 
be continuous and there is no obvious threshold at which the risks become elevated.
In a systematic review of studies looking at pregnancy outcomes, a greater risk of macrosomia 
(OR  =  1.81), peri-natal mortality (OR  =  1.55), pre-eclampsia (OR  =  1.69) and Caesarian Section 
(OR  =  1.37) was observed in women with GDM [12]. Hypoglycaemia was commonly observed in 
neonates whose mother had GDM, but again there was no obvious threshold at which this risk incre-
ased [11]. The neonates were also at a higher risk for jaundice, polycythaemia, respiratory distress and 
hypocalcemia [13]. Finally, fetuses of women with GDM are at higher risk of intrauterine demise, and 
this risk of fetal death in-utero is related to poor glycemic control [14].
Diagnosis and screening
Currently, there are a number of different diagnostic criteria for GDM, which makes comparison of the 
epidemiology and outcomes across different countries difficult (Table I).
Because there is no clear threshold glucose level above which the risk of adverse pregnancy outcome 
increases, it is hard to reach consensus on the diagnostic glucose cut-off levels for GDM. Most diagno-
stic tests use the 2-hour 75gram OGTT, but in United States, the National Diabetes Diagnostic Group 
(NDDG) had favored the use of the 3-hour 100 g OGTT. Following the HAPO Study, the IADPSG had 
advocated using 75 g OGTT, with GDM diagnosed by at least of the criteria: fasting glucose level ≤ 5.1, 
1-hour glucose level ≤ 10.0 mmol/l or 2-hour glucose level ≤ 8.5 mmol/l.
The strategies of screening for GDM during pregnancy vary between different countries, and this may 
be related to the prevalence of diabetes in the region and the resources available. In some countries 
such as Australia, universal screening is recommended [4]. In that country, women who are considered 
at high risk for GDM (women who are obese, belong to certain ethnic groups, have family history of 
diabetes or have previous history of GDM) may be recommended to undergo OGTT after the first an-
tenatal visit in first trimester [4]. This is to exclude women who may already have pre-existing diabetes 
at the time of pregnancy. If found to be negative for GDM, the OGTT can be repeated between 24 and 
28 weeks of gestation [15].
Performing OGTT on all pregnant women is labor intensive and takes up substantial amount of time 
and resources for midwives, obstetrician as well as pathology services. Furthermore, some women 
may not tolerate the glucose loading well, especially for those with persisting morning sickness during 
IADPSG ADA - NDDG ADIPS WHO
Glucose load for glucose tolerance test 75 g 100 g 75 g 75 g
Fasting glucose (mmol/l) ≥ 5.1 ≥ 5.3 ≥ 5.5 ≥7 .0
1-hour glucose level (mmol/l) ≥ 10 ≥ 10.0 - -
2-hour glucose level (mmol/l) ≥ 8.5 ≥ 8.6 ≥ 8.0 ≥ 11.1
3-hour glucose level (mmol/l) - ≥ 7.8 - -
To diagnose GDM, abnormal result in: 1 or more 2 or more 1 or more 1 or more
Table I. Different diagnostic criteria for gestational diabetes
ADA = American Diabetes Association; ADIPS = Australian Diabetes in Pregnancy Society; 
IADPSG = International Association of Diabetes and Pregnancy Study Group; NDDG = National Diabetes 
Diagnostic Group; WHO = World Health Organization
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pregnancy. In one study, the failure rate of OGTT can be as high as 10% (16). It was proposed that wo-
men who are low-risk (age < 25 years, normal pre-pregnant weight, no known diabetes in first-degree 
relatives or member of an ethnic group with low prevalence of GDM) may not need screening, and 
women of average risk may be tested at 24-28 week of gestation [15]. The 1-hour 50g glucose challenge 
test (GCT) has also been advocated for the screening of GDM. This test is more convenient for the 
women as it can be done at any time of the day and does not involve overnight fasting. In some centers 
in Australia, this is used as a screening tool for low-risk women [4]. Women with glucose level above 
7.8 mmol/l following the 50 g GCT will proceed to the 75 g OGTT. In a retrospective analysis of wo-
men who underwent 50 g GCT during pregnancy, at a glucose cut-off value of 11 mmol/l, the positive 
predictive value for GDM was 85.3%, based on the subsequent OGTT [17]. However, for women with 
GCT above 7.8 mmol/l, only 45% of the women actually had GDM on the OGTT. In a systematic re-
view, the sensitivity of the GCT was only 0.74 while the specificity was 0.77, at the glucose cut-off level 
of 7.8 mmol/l [18]. As a result, the GCT cannot replace the 75 g OGTT and is gradually being phased 
out in many centers.
Why is GDM worth treating?
The benefits of intervention in women with GDM had been validated in a two clinical trials. In the 
Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS), tight glycaemic control 
(maintaining fasting or pre-prandial glucose level below 5.5 mmol/l and 2-hour post-prandial glu-
cose level below 7.0 mmol/l) was shown to result in improved pregnancy outcomes [19]. The rate of 
serious peri-natal complications (including death, shoulder dystocia, bone fracture, and nerve palsy) 
was significantly lower among the infants of women randomized to the intervention group than that 
among the infants of women who received standard care [19]. Moreover, at 3 months post-partum, the 
women’s mood and quality of life was consistently better among those who were actively treated for 
GDM [19]. In another study by Landon et al., for women with milder degree of hyperglycaemia, tighter 
glycaemic control (fasting glucose level below 5.3 mmol/l and 2-hour post-prandial glucose level below 
6.7 mmol/l) in women with GDM did not significantly lower the frequency of adverse outcomes (inclu-
ding stillbirth or perinatal death and other neonatal complications) [20]. However, tighter glycaemic 
control reduced the risks of fetal overgrowth, shoulder dystocia, cesarean delivery, and hypertensive 
disorders [20]. In a meta-analysis including 5 randomized clinical trials (including the 2 trials discus-
sed), treatment for gestational diabetes through reducing glucose levels during pregnancy, lowered the 
risk for some peri-natal complications such as shoulder dystocia and pre-eclampsia [21].
The concern of whether the diagnosis and treatment of GDM would cause negative emotional im-
pact on women was partly addressed in ACHOIS. Women in the intervention group, both during the 
antenatal period and 3-months post-partum, were found to have improved health-related quality of 
life, together with a reduction in the incidence of post-partum depression [19]. These findings were 
contrary to reports suggesting women’s perception of their own health may decline with the screening 
process of GDM [22]. Currently there is lack of clear evidence indicating that GDM is associated with 
anxiety or depression [23,24].
Management principles and glycaemic targets
Following diagnosis of GDM, the management of GDM requires a multi-disciplinary approach and 
involves diabetologists, diabetes nurse educator, dietitians as well as obstetricians and midwives. The 
women are usually reviewed by a diabetes nurse educator, and they are informed about the clinical 
implications of GDM and how this can be managed. Self blood glucose monitoring (SMBG) is initiated 
and the women are advised to perform SMBG in the fasting state and 1 or 2 hours post-prandial (i.e. 4 
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times a day). The target BGLs during pregnancy varied in different countries, and are usually based on 
the 2 randomized trials mentioned above (fasting BGL ≤ 5.3 or 5.5 mmol/l, while 2-hour post-prandial 
BGL ≤ 6.7 or 7.0 mmol/l) [19,20]. The ADA guidelines set the glycaemic targets at fasting BGL ≤ 5.8 
mmol/l, 1-hour BGL ≤ 8.6 mmol/l and 2-hour BGL ≤ 7.2 mmol/l [15]. The need to continue SMBG 
as frequent as 4 times a day in women who maintain good diabetes control by 36 weeks’ gestation and 
who do not have evidence of macrosomia on progress fetal ultrasound is uncertain.
There have been some proponents for the determination of BGL targets based on obstetric ultraso-
nic findings [25]. It was proposed that if there is evidence of fetal abdominal circumference excee-
ding 75th percentile on ultrasound, the mother should be subjected to stricter glycaemic control. On 
the other hand, the glycaemic targets can be relaxed if ultrasonic examination has demonstrated 
normal fetal growth. In a randomized study based on this hypothesis, setting glycaemic targets ac-
cording to fetal growth had been shown to be safe with similar pregnancy outcomes when compared 
with standard approach [25]. Inclusion of fetal growth might provide the opportunity to reduce 
glucose testing in low-risk pregnancies. The problem of this approach is that it does not take into 
account of genetic factors which are important determinants of fetal size [5]. Furthermore, most of 
the fetal ultrasound measurements are not corrected for the ethnicity of the parents and may have 
a wide error margin.
The use of glycosylated hemoglobin (HbA1c) as a glycemic goal in the management of GDM is con-
troversial. HbA1c levels did not adequately separate women with normal pregnancy from those with 
GDM, and HbA1c levels decline in normal pregnancy [26]. HbA1c correlated with rates of congenital 
anomalies and early fetal deaths in pregnant women with pre-existing diabetes, but its role in assessing 
women with GDM is unclear [5,27]. Most studies found poor to low correlation between glycosylated 
hemoglobin and mean, fasting, pre-meal, and post-meal blood glucose values. In a study involving 
normal pregnancy or women with GDM, HbA1c did not correlate strongly with OGTT parameters 
and elevated HbA1c was not associated with macrosomia [28]. Findings from HAPO suggested that 
HbA1c was not a useful alternative to OGTT in pregnant women [29].
Medical nutritional therapy and physical activity
All women with GDM should receive counseling from a dietitian, and individualization of medical 
nutrition therapy (MNT), based on maternal weight and height, is appropriate [15]. Apart from trying 
to meet BGL targets, the provision of adequate calories and nutrients for pregnancy needs should be 
part of the dietary advice. In a randomized control study, women who were given MNT in Diabetes 
Clinics were shown to be less likely to require insulin therapy and had a lower HbA1c compared to 
women who were in the usual care group, but there was no significant difference in birth-weight [30].
In the literature, there were few studies looking at the benefits of various diets on obstetric outcomes. 
A diet with low glycaemic index (GI) is often recommended for women with GDM. Studies confirmed 
that the low GI diet is safe and well tolerated in normal pregnancies, but there has not been sufficient 
evidence to demonstrate benefits in pregnancy outcomes in GDM. In a study involving pregnant wo-
men without GDM, those on a low GI diet from second trimester onwards gave birth to infants with 
lower birth-weight, lower ponderal index and lower prevalence of large-for gestational age [31]. On 
the other hand, in a small study involving woman with GDM, those randomized to low GI diet had 
a significantly lower rate of need for insulin therapy [32]. However, the low GI diet did not result in 
a significantly lower fetal birth-weight percentile or ponderal index. The restriction of carbohydrates 
to 35-40% of daily calorie intake was found to reduce maternal BGL and improves maternal and fetal 
outcomes [33].
Women with GDM are advised to start or continue moderate physical exercise during pregnancy, al-
though the impact of exercise on neonatal complications awaits rigorous clinical trials [15]. Again, 
there were not many studies validating the effectiveness of exercise on pregnancy outcomes for women 
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with GDM. There was a small randomized study that showed low level exercise (20 minutes three times 
a week for 6 weeks) for women with GDM resulted in lower fasting glucose levels, lower glucose re-
sponses to a glucose challenge, and lower HbA1c levels [34]. Another similar study demonstrated that 
circuit type exercise three times a week for women with GDM led to lower postprandial glucose levels, 
and delay in the requirement of insulin in those with BMI above 25 [35].
The Institute of Medicine (IOM) has issued some recommendations on weight gain during pregnancy 
[36]. The general principle is that women who are overweight prior to pregnancy should put on smaller 
amount of weight, and underweight women can have greater weight gain during pregnancy [36]. The 
IOM suggested that underweight women can put on up to 40 pounds, while in obese women, they 
should gain no more than 20 pounds during the entire pregnancy. However, it is not clear if the IOM 
recommendations are appropriate for women with GDM and there is currently no guideline regarding 
the optimal weight gain for women with diabetes or GDM.
Insulin therapy
When dietary and lifestyle intervention fail to maintain glucose levels within the specified targets as 
discussed above (upper targets for fasting BGL 5.3-5.8 mmol/l; upper targets for 2-hour post-prandial 
BGL 6.7-7.2 mmol/l), insulin is the pharmacologic therapy of choice [15]. Insulin does not cross the 
placental barrier, and has consistently been shown to reduce fetal morbidities when added to MNT 
[15]. The women are usually started on a small dose, and SMBG is essential to guide the titration of the 
insulin doses.
The proportion of women with GDM requiring insulin therapy varied between different studies, ran-
ging between 20% and 50% [19,37]. Factors that predict requirement of insulin therapy included eleva-
ted BMI, high fasting glucose level on OGTT, and history of previous GDM [37]. Offspring of women 
on insulin therapy had higher birth weight and birth-weight percentile than those of women on MNT, 
but there was no difference in neonatal morbidity including APGAR scores or need for neonatal inten-
sive care support [37]. The need for insulin therapy also varied between different ethnic groups. In a 
cohort of over 800 women, women from south-east Asian background were least likely to need insulin 
therapy (37.2%), while women from Pacific Islands had the highest (65.6%) [38].
The choice of the type of insulin will depend on the woman’s glycaemic profile. For women with ele-
vated fasting BGL, night-time basal insulin (intermediate-acting insulin such as Isophane insulin) is 
usually initiated. For women whose post-prandial BGLs are elevated, regular insulin (short-acting) is 
appropriate. The combination of night-time basal insulin and meal time short-acting insulin is referred 
to basal-bolus regimen. In addition to basal-bolus regimen, twice daily pre-mixed insulin (combi-
nation of short and intermediate-acting insulin) is sometimes used. A study comparing basal-bolus 
regimen with pre-mixed insulin demonstrated that basal-bolus insulin regimen resulted in a lower rate 
of overall neonatal morbidity than the twice daily pre-mixed insulin regimen, and the relative risk for 
hyper-bilirubinaemia and hypoglycaemia was lower [39].
Human insulin is safe to be used during pregnancy, but in the last 10 years, there has been more wi-
despread use of rapid-acting insulin analogues such as Insulin Lispro and Insulin Aspart. Studies had 
shown that these rapid-acting insulin analogues are safe to be used in pregnancy with no evidence 
of increase adverse pregnancy outcomes [40-43]. On the other hand, the safety profiles of the more 
long-acting insulin analogues such as Insulin Glargine and Insulin Detemir have not been fully vali-
dated for use in pregnancy. Emerging evidence suggests that the use of these long-acting analogues 
does not result in adverse maternal or fetal outcomes [44-46]. For women with pre-existing type 1 
diabetes, it may be appropriate to continue these basal insulin analogues during pregnancy, since 
changing insulin therapy during pregnancy can result in a period of glycometabolic instability. These 
long-acting insulin analogues may also be considered if the woman develops an allergic reaction to 
Isophane insulin.
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Oral anti-hyperglycaemic agents
Oral anti-hyperglycaemic agents (AHG) are usually not recommended for use during pregnancy 
because of the potential risks of neonatal hypoglycemia and teratogenicity associated with placental 
transfer of the drug to the fetus [47]. However, the use of a few oral AHG has received considerable 
attention following a number of clinical studies. In South Africa, metformin had been used for over 
30 years, but its safety and effectiveness was not formally assessed [48,49]. In the Metformin In Gesta-
tional Diabetes (MiG) trial where 751 women with GDM who failed MNT were randomized to either 
insulin therapy or metformin, the use of metformin in late 2nd and 3rd trimester in women with GDM 
was not associated with increased peri-natal complications as compared with insulin therapy [50]. In 
addition, more women in the metformin group preferred their assigned therapy compared to those in 
the insulin group. As part of this trial, in a small number of women where cord blood was assessed, it is 
important to note that placental transfer of metformin is considerable, and the fetal level of metformin 
is about half that of the maternal level [51]. In the follow-up study of MiG, up to the age of 2 years, 
children who were exposed to metformin in-utero had larger measures of subcutaneous fat, but overall 
body fat was the same as in children whose mothers were treated with insulin alone [52]. The findings 
of MiG are promising but we should await longer term follow up of the offspring of women in the 
metformin group.
In United States, there is emerging interest for the use of sulphonylureas, especially glyburide, during 
pregnancy. In a randomized study comparing glyburide with insulin therapy, women treated with gly-
buride achieved similar degree of glycaemic control to those in the insulin group [53]. The risks of ma-
crosomia, respiratory distress, neonatal hypoglycaemia and need for neonatal intensive care support 
were not different between the 2 groups. Compared to metformin, placental transfer of glyburide was 
minimal [54]. Currently neither metformin or glyburide is endorsed by Food and Drug Authority for 
use during pregnancy [15].
In a meta-analyses of studies including over 1,300 women with GDM, treatment with oral AHG (essen-
tially the 2 medications: glyburide and metformin) achieved comparable glycaemic levels as those on 
insulin therapy, and use of AHG was not associated with increased peri-natal complications or macro-
somia [47,55]. Nevertheless, the total number of women included in these studies was still quite small, 
and long term effects on the off-spring were not available. At the moment, due to lack of clinical studies, 
AHGs such as acarbose, thiazolidinediones, dipeptidyl-peptidase 4 inhibitor and glucagon-like peptide 
1 analogues should not be used during pregnancy. More safety data will be required before these agents 
can become part of routine management of diabetes during pregnancy.
Obstetrics management and delivery
There has been a lack of clinical studies that evaluate the optimal obstetric management of women with 
GDM. The consensus is that all women with GDM should monitor fetal movement during the last 8-10 
weeks of pregnancy and any reduction in the perception of fetal movement should be reported imme-
diately [56]. The use of fetal imaging using ultrasound is often performed in third trimester to detect 
any accelerated fetal growth. This may be particularly important in women with poor glycaemic con-
trol or women who are on insulin therapy. There is certainly a need to refine fetal and pelvic imaging 
techniques to help identify maternal-fetal pairs for Caesarian section to avoid complications such as 
shoulder dystocia [56]. The main dilemma revolves balancing the maternal and fetal risks: the chance 
of damage to the mother with GDM from cesarean delivery versus the chance of adverse impact on the 
fetus from events such as shoulder dystocia at vaginal delivery [56].
In the area of optimal timing and mode of delivery to avoid fetal injury, large well-controlled prospec-
tive studies do not currently exist [56]. In a systematic review on the delivery management of women 
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with GDM, one randomized control study demonstrated that active induction at term resulted in lower 
rate of macrosomia than expectant labour management [57]. However, the risks of other outcomes 
such as shoulder dystocia, neonatal hypoglycemia, or perinatal deaths were not different. Due to the 
lack of well designed studies, there is little data to recommend the optimal timing and mode of deli-
very in order to minimize the risk of fetal injury. Having GDM alone is not sufficient indication for 
Caesarean section or for delivery prior to 38th weeks of gestation [15]. Continuation of pregnancy for 
women with uncomplicated GDM up to 10 days past the term date may be acceptable provided that 
fetal wellbeing is ensured through careful monitoring [4].
Maintaining good glycaemic control during labor is important to reduce the risk of fetal acidosis and 
neonatal hypoglycemia [58]. The risk of other adverse neonatal metabolic outcomes (such as hyperbi-
lirubinemia or hypocalcemia) is also related to both ante-partum and intra-partum maternal hyper-
glycemia and appears to increase with the degree of maternal hyperglycemia. The American College of 
Obstetricians and Gynecologist and the American College of Endocrinology recommended a glucose 
target of between 3.9 and 6.1 mmol/l during the intra-partum period [59,60]. During labor, especially 
for women who are on insulin therapy, it is common to replace subcutaneous insulin injections with 
intravenous insulin infusion (with or without glucose infusion at the same time), which allows fine 
adjustment of insulin rates to maintain strict glycaemic control. For women who have well controlled 
GDM on MNT alone, insulin infusion is usually not required.
Post-partum care
Following parturitions, especially after the delivery of the placenta, the hyperglycaemic effects from 
placental hormones dissipate rapidly, and the glycometabolic profile of women with GDM returns to 
their pre-pregnancy state almost immediately. However, some women with GDM actually have undia-
gnosed type 2 diabetes mellitus, and hence it is prudent to monitor the women’s BGL up to 48 hours 
post-partum. It is important that women with GDM are made aware of their increased risk of recurrent 
GDM in their subsequent pregnancies as well as their increased risk of developing type 2 diabetes in 
the future. Predictors of the development of type 2 diabetes included elevated maternal BMI, need for 
insulin therapy during pregnancy, and glucose level during OGTT at the time of diagnosis of GDM 
[61]. The rates of development of type 2 diabetes are much higher in several non-European ethnic 
groups. The prevalence of type 2 diabetes in Polynesian women was reported to be 30%, while for 
Latino women, they have a 47% cumulative incidence of type 2 diabetes 5 years after delivery [4,62]. 
It is therefore important that these women should have a repeat OGTT, probably about 6-12 weeks 
post-partum. The OGTT should be repeated every 2 years thereafter to allow early detection of type 2 
diabetes [4]. The development of cardiovascular disease was found to be higher in women with GDM 
and this occurred at a younger age, independent of the metabolic syndrome and type 2 diabetes [63] . 
It is therefore important to also address the various reversible cardiovascular risk factors such as smo-
king, obesity, hypertension, and hyperlipidemia, and this should be part of the post-partum care for 
this group of women.
Because women with GDM have such high risk of developing type 2 diabetes mellitus later in life, this 
group of patients may provide a unique opportunity to study the early pathogenesis of diabetes. They 
represent a high risk group where intervention may be worthwhile in preventing the development of 
diabetes or vascular disease. As part of a sub-analysis of the Diabetes Prevention Program, women with 
a history of GDM had a substantially higher risk of developing diabetes later in life compared to parous 
women without GDM [64]. For women who had GDM in the past, both intensive lifestyle and metfor-
min therapy reduced the incidence of diabetes by approximately 50% compared with the placebo group, 
whereas this reduction was 49 and 14%, respectively in women whose previous pregnancies were not 
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complicated by GDM. However, routine use of metformin in women with a history of GDM to prevent 
diabetes is not justified. The Troglitazone in Prevention of Diabetes (TRIPOD) study was conducted 
on Hispanic women with recent GDM, and those who were randomized to treatment with the insulin-
sensitizing drug troglitazone for a median duration of 30 months had a 55% reduction in the incidence 
of type 2 diabetes [65]. Protection from diabetes was closely linked to initial reductions in endogenous 
insulin requirements and ultimately associated with stabilization of pancreatic cell function [65].
As for the offspring of women with GDM, infants of women with gestational diabetes have increased 
body fat compared with weight-matched infants of control women [66]. The birth weight of these in-
fants normalized by one year, but the weight increased again during early childhood. The offspring of 
mothers with GDM and who were born large for gestational age were at significant risk of developing 
metabolic syndrome in childhood [67]. The intra-uterine exposure to hyperglycaemia may have im-
portant glycometabolic implications for the offspring later in their life. In a study looking at parental 
history of diabetes, GDM was twice as common in the daughters of mothers with diabetes (11%) than 
fathers with diabetes (5%) [68]. The excess of maternal transmission of diabetes implies an epigenetic 
effect of in-utero hyperglycaemia acting in addition to genetic factors to produce diabetes in the next 
generation. More research is needed to assess the level of glycaemic control during pregnancy on the 
glycol-metabolic state of offspring when they reach adulthood.
Conclusion
The rise in the incidence of GDM mirrors that of type 2 diabetes in many countries, and it is draining 
a significant amount of resources for diabetes services world-wide. Optimal management of women 
with GDM is important in ensuring good pregnancy outcomes. Risk stratification may be invaluable, 
as this may allow greater resources to be directed to women at higher risk, and avoidance of over-tre-
atment of women at low risk. To be able to achieve this, there is a need for a multi-disciplinary team 
approach that includes diabetologists, diabetes nurse educators, dietitians, midwives and obstetricians. 
Good communication between these clinicians (in relaying information including maternal glycome-
tabolic state and fetal biophysical profile) is essential in assessing the risk profile of the pregnancy and 
in determining the most favorable timing and method of delivery of women with GDM. Ongoing re-
search will be needed in assessing the safety profiles of the newer AHG as well as basal insulin analo-
gues during pregnancy, and consensus is required in determining the optimal obstetric management of 
women with GDM. Finally, greater effort should be made in devising best strategy to prevent the deve-
lopment of type 2 diabetes in these women as well as their offspring.
Question for further research
• Areas that need further research include:
• To determine the most appropriate medical nutrition therapy for women with GDM, and the 
effects and safety of different diets on pregnancy outcomes
• The safety profile of various oral anti-hyperglycaemic medications as well as the long-acting in-
sulin analogues to be used during pregnancy
• Strategies in the obstetric management of women with GDM including timing and frequency 
of ultrasound and timing of delivery
• Intra-partum management of women with GDM
• Long term follow-up of women with GDM: strategies to reduce their risk cardiovascular disease
• To assess the relationship between level of glycaemic control during pregnancy and the glyco-
metabolic profile of offspring of women with GDM
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